Why the study?
Coronary artery disease in women presents differences in clinical presentation, pathophysiology, and outcomes, raising the question of whether sex remains an issue in percutaneous coronary intervention.
Does percutaneous coronary intervention have different outcomes and complication rates in women compared to men?
Does percutaneous coronary intervention have different outcomes and complication rates in women compared to men?
Answers are grounded in this paper and cite their sources.
Despite improvements in techniques and devices, women undergoing PCI still face higher risks of bleeding, vascular complications, and worse overall prognoses compared to men, highlighting the need for sex-specific investigations and bleeding avoidance strategies.
Coronary artery disease among women presents differences in terms of clinical presentation and pathophysiology. To date, women present worse prognoses with more events and higher mortality rate. One the one hand, they are less likely addressed for invasive therapy. One the other hand, revascularization procedures, whether by bypass or by percutaneous coronary intervention, are associated with higher rates of complications and poorer prognosis. Despite higher risk factor burden and comorbidity, women are less affected by obstructive disease and plaque characteristics are more favorable than among men. Abnormalities of endothelial function and micro vascular flow reserve could explain part of the high prevalence of symptoms of angina observed among women. Due to the worse prognosis of microvascular dysfunction, particularly in women, proper diagnosis is mandatory and deserve invasive management. Outcome following ST elevation myocardial infarction is still more severe among women with higher in-hospital mortality, but sex discrepancies are observed even in elective percutaneous coronary intervention. However, improvement of techniques, drugs and devices benefited to both men and women and tend to decrease gender gap. Especially, changes in the design of newer-generation drug-eluting stents (DES) may be particularly important for women. Female sex remains a potent predictor of higher risk of bleeding and vascular complication; thus important efforts should be promoted to develop bleeding avoidance strategies. Sex-based differences still deserve dedicated investigations in terms of physiopathology, particular hormonal impacts, and specific responses to drugs and devices.
No takes yet. Share an insight, caveat, or question.
Stéphane Manzo‐Silberman (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: